Alcohol-related liver disease (ARLD), also called alcohol-associated liver disease, needs assessment of liver injury and support for alcohol treatment. Confidence is high that suspected serious complications and severe withdrawal need medical care. Stopping alcohol is the clinical goal for established ARLD, but dependence may make an unsupervised sudden stop dangerous. No independently established liver-cleanse supplement replaces a safe treatment plan. Current liver-disease overview; Withdrawal safety.
- Alcohol-associated fatty liver, hepatitis and cirrhosis are different clinical findings within the disease spectrum.
- Liver injury can be present without obvious symptoms; assessment should not wait for jaundice.
- Safe withdrawal and longer-term alcohol support are separate needs, both requiring a plan.
- Advanced disease changes medicine choice; do not borrow an alcohol-treatment prescription from someone else.
- Nutrition and selected deficiency treatment are clinical care, not evidence that a liver-detox product reverses disease.
Table of contents
- Evidence summary
- What is alcohol-related liver disease?
- How it works
- The evidence-based treatments
- Supplement and lifestyle evidence
- What works and what does not
- Risks and side effects
- Important interactions
- Who needs special assessment
- Clinician-led treatment and use
- Animal and in-vitro evidence
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Alcohol and liver care | Current NHS/DHSC clinical pathways | Public institutions; full expert/trial finance incomplete | Safe withdrawal plus ongoing alcohol and liver support. |
| Severe alcohol-associated hepatitis | ACG selected corticosteroid pathway; STOPAH safety | Public/society support with author commercial ties | Clinical context and infection caution; independent efficacy excluded. |
| Thiamine / nutrition support | Current neurological and nutrition guidance | Public guidance does not financially clear every supporting trial | Clinician-led risk/deficiency care; no personal dose or liver cure claim. |
| Relapse-prevention medicines | Stage-specific UK pharmacological guidance | Contributor and trial finance not exhaustively traced | Advanced disease changes suitability; no independent medicine ranking. |
| Milk thistle / liver detox | NCCIH evidence and product-quality uncertainty | Public publisher; underlying trial money uncleared | No universal independent cure or treatment replacement. |
What is alcohol-related liver disease?
ARLD describes liver damage associated with alcohol exposure. Fat accumulation is called steatosis; alcohol-associated hepatitis includes inflammation and injury, and cirrhosis means advanced scarring. These names help frame assessment, but do not establish the person’s current severity without the clinical findings. Disease spectrum.
A history of drinking should prompt honest assessment rather than close the diagnostic process. Other liver conditions may coexist. Clarify what has been assessed, what cause is established and whether a further test is needed; do not assume every abnormality is explained by the same label.
Alcohol-use disorder concerns harmful use, impaired control and, for some people, dependence. Liver disease and dependence are related questions but are not interchangeable diagnoses. Tell the team about craving, morning drinking, withdrawal symptoms and difficulty reducing intake so support fits the actual risks. Alcohol-use disorder assessment.
How it works
Alcohol-related disease can affect the liver’s structure and function. Once cirrhosis develops, complications can include abdominal fluid, internal bleeding, brain-related changes and liver failure. Advanced disease requires monitoring that goes beyond a single blood result. Advanced-liver complications.
Current UK guidance stresses that normal liver blood tests do not exclude cirrhosis. Assessment may include fibrosis testing in an appropriate pathway; the test should lead to an explained decision and follow-up, not just a number handed to the patient. Primary-care assessment.
Medical history, laboratory tests and imaging are interpreted together. Selected biopsy may help when the diagnosis or cause remains uncertain. Ask what the result means, which question remains unanswered and who will act on it. Diagnostic assessment.
The evidence-based treatments
Clinical care aims to stop further alcohol-related injury while treating established complications. A GP, alcohol service and liver specialist may share responsibility. Talking therapies, practical support, relapse-prevention care and selected medicines can form part of the plan. Treatment and support.
Advanced ARLD with withdrawal requires experienced specialist management; current UK guidance recommends hospital admission for withdrawal in advanced disease. This is why a generic at-home detox schedule is unsuitable. The team must consider both withdrawal and liver-related brain changes. Advanced-liver withdrawal care.
Severe alcohol-associated hepatitis is an acute clinical problem. Clinicians may consider corticosteroids for selected patients after assessment and review of contraindications and response. This guide reports a guideline pathway, not an independent efficacy endorsement or a self-treatment regimen. Severe-hepatitis guidance.
Cirrhosis complications need their own management, such as fluid, bleeding or encephalopathy care. Transplant assessment may be relevant in selected advanced disease. A referral is an assessment process, not a guarantee of eligibility or transplantation. Complication and transplant care.
Supplement and lifestyle evidence
Poor intake and nutrient problems need a practical nutrition review. In cirrhosis, meal planning should provide adequate energy and protein and avoid prolonged fasting; selected deficiencies may need treatment. Ask for dietetic help if nausea, early fullness, affordability or fear of foods prevents adequate eating. Advanced-liver nutrition.
Thiamine treatment can be part of care for people at risk of alcohol-related neurological harm. Suspected Wernicke’s encephalopathy requires emergency treatment in an acute medical setting, including clinician-directed intravenous thiamine. Taking an ordinary supplement at home is not a reason to delay assessment. Brain-damage and Wernicke’s guidance.
Milk thistle is marketed for liver health, but NCCIH does not find enough high-quality evidence for firm clinical conclusions and notes allergy and product variability. That uncertainty should stay visible rather than become a promise that it repairs alcohol-related injury. Milk-thistle evidence limits.
Discuss the purpose of each supplement. Replacing a documented deficiency, supplying nutrition when eating is inadequate and trying to treat liver scarring are different claims. Ask which outcome is expected and how it will be checked; no product is given a universal independently established cure claim here.
What works and what does not
A successful plan needs goals for both liver health and alcohol treatment. Withdrawal care manages immediate risk; ongoing support addresses the period after withdrawal. Ask how services will coordinate instead of assuming that a short admission completes treatment.
Care should remain accessible when someone is ambivalent or has not achieved abstinence. Current UK guidance encourages engagement rather than excluding people from liver care because they cannot initially accept or reach that goal. Access and coordinated care.
Keep reported outcomes precise. Improvements in symptoms or a blood marker do not establish that advanced disease has resolved. Likewise, an acute-hepatitis treatment cannot be assumed to prevent every long-term alcohol-related complication. No independent medicine-benefit conclusion is drawn from the commercially linked STOPAH investigators or ACG panel.
Risks and side effects
Vomiting blood, black sticky stool, sudden confusion or difficulty staying awake require emergency assessment. New marked abdominal pain, breathing difficulty or severe deterioration also need urgent help. Do not drive yourself if impaired or explain these symptoms as a normal detox reaction. Emergency warning signs.
Severe withdrawal with seizures, hallucinations, major agitation or confusion is an emergency. Dependence can make suddenly stopping dangerous; seek medical help to arrange withdrawal safely. A person who seems confused may need assessment for more than one cause. Severe withdrawal signs.
Corticosteroid decisions include infection risk. The original STOPAH trial reported more serious infections among prednisolone recipients; its original public grant and industry-fee disclosures are both recorded below. This is a harms reminder, not a treatment comparison or reason to stop a prescribed steroid yourself. Original trial safety context.
Advanced liver disease also changes food-safety precautions. Avoid raw or undercooked fish, shellfish or meat and unpasteurised milk products when advised for cirrhosis. If eating is difficult, combine safety advice with nutrition support rather than expanding restrictions without help. Cirrhosis food safety.
Important interactions
Relapse-prevention medicines require assessment of liver and kidney function and concurrent medicines. Current UK guidance advises against disulfiram and naltrexone in advanced ARLD, while options for less severe disease differ. It does not make any medicine universally suitable. Stage-specific medicine precautions.
Tell the prescribing team about pain treatment, sedatives, sleep medicines and any alcohol-treatment drugs already used. Opioid use matters when naltrexone is being considered. Medicines prescribed by different services need a coordinated review; this guide provides no start, stop or substitution instructions.
In cirrhosis, check before using over-the-counter painkillers, sleep aids or herbal products. A supplement label saying liver support does not establish safety in a liver that is already injured. Bring the containers or an accurate ingredient list so combinations can be reviewed. Medicine and supplement review.
Who needs special assessment
Advanced cirrhosis, previous complicated withdrawal, serious physical illness or inadequate home support can change where care should take place. A clinician should assess these practical risks alongside the diagnosis. A plan that depends on support the person does not actually have needs revision.
Pregnancy or plans for pregnancy require prompt support to stop alcohol safely and specialist review of treatment. Children and young people need an age-appropriate pathway. Do not transfer adult withdrawal or relapse-prevention regimens into those settings. Pregnancy and alcohol support.
If someone has cognitive changes, involve carers with appropriate consent and ask whether information or appointments need adapting. Hospital guidance stresses assessment, multidisciplinary care and continuing support after discharge; difficulty participating is a reason to manage risk and reassess, not to dismiss the person. Hospital care and continuity.
Clinician-led treatment and use
Tell the team the actual pattern of drinking, the last drink, previous withdrawal problems, nutrition difficulties and all medicines. These details affect safe planning. If a change is proposed, clarify how withdrawal risk and liver disease are both being addressed.
Ask for a written plan covering referral, immediate safety, planned tests and the contact route if symptoms worsen. After hospital treatment, confirm who coordinates liver follow-up and ongoing alcohol care, and whether nutrition or neurological concerns need another specialist.
If a relapse occurs, recontact the service and describe what happened. Ask whether the plan, setting or practical support needs changing. Treatment goals should be clear enough to review without turning setbacks into a reason to disengage from medical care.
This guide gives no personal alcohol-taper, benzodiazepine, corticosteroid, thiamine, calorie or supplement schedule. The appropriate regimen depends on assessment and monitoring. Bring questions about side effects, affordability and transport so the plan can be carried out in daily life.
Animal and in-vitro evidence
No animal or test-tube finding establishes an ARLD cure here. Antioxidant activity, reduced fat droplets, altered gut microbes or inflammatory markers are not proof that a product prevents bleeding, liver failure or death. No laboratory dose is converted into a human detox regimen.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 11 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
The original ACG guideline reports NIH/NIAAA and ACG support alongside commercial author competing interests. STOPAH had an NIHR public trial grant, but its original paper also disclosed pharmaceutical lecture/consulting fees. Those sources are excluded from independent efficacy conclusions; clinical safety and care context remain clearly labelled.
DHSC guidance is publicly led and its statutory finances were checked. The contributor roster names professionals and lived-experience members but does not supply a complete financial-interest registry. Public authorship therefore does not clear every expert or underlying trial. NIDDK’s acknowledged reviewer relationships remain disclosed as in the cirrhosis guide.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: alcohol-related liver disease, July 2026 | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. Video identifies hepatologist Mark Wright; complete external contributor relationships and page-specific payments unknown. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NHS: alcohol-use disorder, April 2026 | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NHS: cirrhosis, February 2025 | UK public health service; statutory annual accounts provenance. Page-specific sponsor/expert payments not disclosed; individual-provider and research income can differ. | United Kingdom; NHS England national patient information. | Tier 1 institutional education, provisional; complete page financing unknown. | B, provisional — care accountability and clear triage guidance; simplified advice, not a trial-level financial audit. |
| NCCIH: milk thistle, February 2025 | NIH federal agency; NCCIH budget information. Page-level commercial sponsor not named; underlying review/trial funding not exhaustively traced. | United States; NCCIH, Bethesda, Maryland; federal education. | Tier 1 institution; underlying trials unclassified. | B, provisional — public review and explicit uncertainty favor accuracy; an older synthesis does not certify any product or remove trial sponsorship. |
| NIDDK: cirrhosis diagnosis | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. Series acknowledges UCSF reviewer Bilal Hameed; his 2021 original study disclosure records Gilead and other pharmaceutical grants/advice. This does not establish payment for this education page. | United States; NIDDK Bethesda, Maryland; acknowledged expert UCSF, California. Gilead headquarters Foster City, California; complete historical commercial jurisdictions not mapped. | Tier 2 context — publicly funded publisher with acknowledged commercially linked reviewer; page payment unverified. | C, provisional — public scientific review; acknowledged reviewer industry relationships, June 2023 synthesis and incomplete underlying trial finance. Clinical context only. |
| NIDDK: cirrhosis treatment | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. Series acknowledges UCSF reviewer Bilal Hameed; his 2021 original study disclosure records Gilead and other pharmaceutical grants/advice. This does not establish payment for this education page. | United States; NIDDK Bethesda, Maryland; acknowledged expert UCSF, California. Gilead headquarters Foster City, California; complete historical commercial jurisdictions not mapped. | Tier 2 context — publicly funded publisher with acknowledged commercially linked reviewer; page payment unverified. | C, provisional — public scientific review; acknowledged reviewer industry relationships, June 2023 synthesis and incomplete underlying trial finance. Clinical context only. |
| NIDDK: cirrhosis nutrition | NIH/HHS public institution; federal budget documentation. No page-level commercial sponsor identified; outside-expert financial disclosures not supplied. Series acknowledges UCSF reviewer Bilal Hameed; his 2021 original study disclosure records Gilead and other pharmaceutical grants/advice. This does not establish payment for this education page. | United States; NIDDK Bethesda, Maryland; acknowledged expert UCSF, California. Gilead headquarters Foster City, California; complete historical commercial jurisdictions not mapped. | Tier 2 context — publicly funded publisher with acknowledged commercially linked reviewer; page payment unverified. | C, provisional — public scientific review; acknowledged reviewer industry relationships, June 2023 synthesis and incomplete underlying trial finance. Clinical context only. |
| UK alcohol guideline: pharmacological care | DHSC-led public guidance. Original 2024–25 accounts document parliamentary/public funding; development method describes expert/lived-experience input and consensus where evidence is limited. Contributor roster is not a complete financial-interest registry; page/trial finances not fully cleared. | United Kingdom; DHSC, London; development across the four UK nations. Local provider income differs. | Tier 1 institutional context; outside-expert and underlying trial independence unverified. | C, provisional for independence — public clinical accountability and transparent method; full author/trial financial audit missing, consensus and policy/resource priorities remain. |
| UK alcohol guideline: primary/community care | DHSC-led public guidance. Original 2024–25 accounts document parliamentary/public funding; development method describes expert/lived-experience input and consensus where evidence is limited. Contributor roster is not a complete financial-interest registry; page/trial finances not fully cleared. | United Kingdom; DHSC, London; development across the four UK nations. Local provider income differs. | Tier 1 institutional context; outside-expert and underlying trial independence unverified. | C, provisional for independence — public clinical accountability and transparent method; full author/trial financial audit missing, consensus and policy/resource priorities remain. |
| UK alcohol guideline: acute hospitals | DHSC-led public guidance. Original 2024–25 accounts document parliamentary/public funding; development method describes expert/lived-experience input and consensus where evidence is limited. Contributor roster is not a complete financial-interest registry; page/trial finances not fully cleared. | United Kingdom; DHSC, London; development across the four UK nations. Local provider income differs. | Tier 1 institutional context; outside-expert and underlying trial independence unverified. | C, provisional for independence — public clinical accountability and transparent method; full author/trial financial audit missing, consensus and policy/resource priorities remain. |
| UK alcohol guideline: physical health | DHSC-led public guidance. Original 2024–25 accounts document parliamentary/public funding; development method describes expert/lived-experience input and consensus where evidence is limited. Contributor roster is not a complete financial-interest registry; page/trial finances not fully cleared. | United Kingdom; DHSC, London; development across the four UK nations. Local provider income differs. | Tier 1 institutional context; outside-expert and underlying trial independence unverified. | C, provisional for independence — public clinical accountability and transparent method; full author/trial financial audit missing, consensus and policy/resource priorities remain. |
| UK alcohol guideline: brain damage | DHSC-led public guidance. Original 2024–25 accounts document parliamentary/public funding; development method describes expert/lived-experience input and consensus where evidence is limited. Contributor roster is not a complete financial-interest registry; page/trial finances not fully cleared. | United Kingdom; DHSC, London; development across the four UK nations. Local provider income differs. | Tier 1 institutional context; outside-expert and underlying trial independence unverified. | C, provisional for independence — public clinical accountability and transparent method; full author/trial financial audit missing, consensus and policy/resource priorities remain. |
| ACG alcohol-associated liver disease guideline, 2024 | Original financial statement, page 19: NIH/NIAAA author grants and ACG faculty-development grant. Authors report competing interests involving Echosens, Novartis, Merck, Durect, AbbVie, Galectin, Bausch/Salix, Aldeyra and Pleiogenix. Complete relationship types/backer ownership not mapped. | United States ACG/clinical institutions plus Hospital Clinic Barcelona, Spain. Complete commercial backer jurisdictions not mapped. | Tier 3 — disclosed commercial author relationships. | C, provisional — detailed GRADE/clinical analysis; author commercial ties, variable evidence strength and search through December 2022. |
| STOPAH original trial, 2015 | Original funding and disclosures, page 9: NIHR HTA grant 08/14/44. Thursz reports Gilead, Bristol-Myers Squibb, AbbVie and Abbott lecture/consulting fees; Allison reports Norgine consulting fees. Public trial grant does not erase those relationships. | United Kingdom multicentre trial; NIHR public programme. Complete historical corporate ownership/jurisdictions not traced. | Tier 3 — author industry fees despite public trial support. | C, provisional — randomised multicentre design and original disclosure; commercial author ties, selected severe-hepatitis population and older care. |
Frequently asked questions
Can I have liver injury without jaundice?
Yes. Lack of obvious symptoms does not establish that the liver is unaffected.
Does stopping drinking mean I no longer need follow-up?
Ask the liver team. The established stage and complications determine ongoing care.
Is a sudden stop always safe?
No. Dependence may require medically managed withdrawal; severe withdrawal symptoms are an emergency.
Is thiamine a liver cleanse?
No. It addresses deficiency-related neurological risk within an assessed clinical plan.
Can I still get help if I am not ready for abstinence?
Seek care. Current guidance supports engagement and harm-reduction care while working toward the appropriate goal.
Sources and funding notes
Current NHS ARLD page (July 2026) replaces older separate-page routes; current alcohol-use-disorder guidance is April 2026. UK DHSC clinical manual (November 2025, updated April 2026), development/contributor roster and original statutory funding were checked. The ACG guideline original financial disclosures and STOPAH original NIHR support plus industry fees were verified; neither is used for independent efficacy. Advanced-liver medicine cautions are qualified and no individual withdrawal, prescription or supplement regimen is provided.
- NHS: alcohol-related liver disease, July 2026 — Current definition, stages and early-care context.
- NHS: alcohol-use disorder, April 2026 — Dependence, withdrawal red flags and available support.
- NHS: cirrhosis, February 2025 — Advanced-liver complications and emergency warning signs.
- NCCIH: milk thistle, February 2025 — Evidence and product-quality uncertainty; not a trial-independence clearance.
- NIDDK: cirrhosis diagnosis — Laboratory, imaging and selected biopsy context; June 2023.
- NIDDK: cirrhosis treatment — Cirrhosis complication care and medicine-review safety.
- NIDDK: cirrhosis nutrition — Advanced-liver nutrition and food safety.
- UK alcohol guideline: pharmacological care — Liver-stage-specific medicine precautions; advanced disease and withdrawal need hospital/specialist care. Published November 2025, manual updated April 2026.
- UK alcohol guideline: primary/community care — Normal liver blood tests do not exclude cirrhosis; referral and follow-up. Published November 2025, manual updated April 2026.
- UK alcohol guideline: acute hospitals — Hospital assessment, nutrition/complication review and discharge coordination. Published November 2025, manual updated April 2026.
- UK alcohol guideline: physical health — Liver/alcohol care pathways and access despite ambivalence about abstinence. Published November 2025, manual updated April 2026.
- UK alcohol guideline: brain damage — Wernicke’s emergency care and thiamine safety context. Published November 2025, manual updated April 2026.
- ACG alcohol-associated liver disease guideline, 2024 — Clinical severe-hepatitis and medicine-safety context only; no independent efficacy ranking. DOI 10.14309/ajg.0000000000002572.
- STOPAH original trial, 2015 — Funding provenance and steroid-associated serious-infection safety context only; efficacy excluded from independent verdict. DOI 10.1056/NEJMoa1412278.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.